Abstract
INTRODUCTION:Status migrainosus is a complication of migraine, patients are often hospitalized for diagnostic studies and/or treatment. An alternative for the management, are the outpatient infusion center, minimizing hospital admissions and unnecessary examinations.
OBJECTIVE:To determine the therapeutic response and associated factors in patients with migraine status treated in an infusion room.
METHODOLOGY:Retrospective cohort study whose population was migraine patients attended in an infusion room between February and August 2019. Information on sociodemographic, clinical, and therapeutic management variables was obtained from the review of medical records. The response was evaluated with an analogous pain scale at the beginning and at the end of the treatment; Those patients with improvement greater than 50 % were considered responders. Predictive factors of therapeutic response were evaluated using logistic regression.
RESULTS:124 patients were included, with an average age of 36 (SD = 12 years), 82.3 % were women. The average duration of the migraine state was 8 (SD = 4 days), 73.4 % of the cases were without aura and 97 (78.2 %) were responders. The predictors of good response were the use of dexamethasone (OR: 4.3) and not using lidocaine (OR: 6.0).
CONCLUSIONS:Most of the patients had a good response, which identified the outpatient infusion center as a good alternative to inpatient treatment of headache. In our experience, the steroid constitutes a fundamental part of the management of the status migrainosus once it has been established.
References
Saylor D, Steiner TJ. The Global Burden of headache. Semin Neurol. 2018;38(2):182-90. Disponible en: http://dx.doi.org/10.1055/s-0038-1646946
Organizzazione mondiale della sanita. Atlas of headache disorders and resources in the world 2011 : a collaborative project of the World health organization and Lifting the burden. Genève, Switzerland: World Health Organization; 2011.
Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. 2019;20(1):41. Disponible en: http://dx.doi.org/10.1186/s10194-019-0993-0
Vincent M, Wang S. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia. 2018;38(1):1-211.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis. Cephalalgia. 2014;34(8):633-7. Disponible en: http://dx.doi.org/10.1177/0333102414520763
Chua AL, Grosberg BM, Evans RW Status migrainosus in children and adults. Headache. 2019;59(9):1611-23. Disponible en: http://dx.doi.org/10.1111/head.13676
Xu F, Arakelyan A, Spitzberg A, Green L, Cesar P-H, Csere A, et al. Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus. Clin Neurol Neurosurg. 2019;178:31-5. Disponible en: http://dx.doi.org/10.1016/j.clineuro.2019.01.007
Lipton RB, Stewart WF, Stone AM, Láinez MJA, Sawyer JPC. Stratified care vs step care strategies for migraine: The disability in strategies of care (DISC) study:A randomized trial. JAMA. 2000;284(20):2599. Disponible en: http://dx.doi.org/10.1001/jama.284.20.2599
Marmura MJ, Hou A. Inpatient management of migraine. Neurol Clin. 2019;37(4):771-88. Disponible en: http://dx.doi.org/10.1016/j.ncl.2019.07.007
Tepper SJ. Acute treatment of migraine. Neurol Clin. 2019;37(4):727-42. Disponible en: http://dx.doi.org/10.1016/j.ncl.2019.07.006
Bohorquez S, Pozo-Rosich P. Protocolo diagnóstico y terapéutico de la cefalea de reciente comienzo. Status migrañoso. Medicine. 2019;12(71):4181-6. Disponible en: http://dx.doi.org/10.1016/j.med.2019.01.014
Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;15:2. Disponible en: http://dx.doi.org/10.1186/1129-2377-15-2
Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Canadian headache society guideline: Acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(S3):S1-3. Disponible en: http://dx.doi.org/10.1017/s0317167100017819
Diener H-C, Holle-Lee D, Nàgel S, Dresler T, Gaul C, Góbel H, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin transl neurosci. 2019;3(1):2514183X1882337. Disponible en: http://dx.doi.org/10.1177/2514183x18823377
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. Disponible en: http://dx.doi.org/10.1111/head.12499
Muñoz Joe, Volcy Michel, Sobrino Fidel, Ramírez Sergio, Uribe Bernardo, Pradilla Gustavo et al . Consenso de expertos de la Asociación Colombiana de Neurología para el tratamiento preventivo y agudo de la migraña. Acta Neurol Colomb. 2014; 30( 3 ): 175-185. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482014000300008&lng=en.
Singh TD, Cutrer FM, Smith JH. Episodic status migrainosus: A novel migraine subtype. Cephalalgia. 2018;38(2):304-11. Disponible en: http://dx.doi.org/10.1177/0333102416686341
Aicher B, Peil H, Peil B, Diener H-C. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia. 2012;32(3):185-97. Disponible en: http://dx.doi.org/10.1177/03331024111430856
Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-58. Disponible en: http://dx.doi.org/10.1016/s0304-3959(01)00349-9
Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain. 2001;94(2):131-2. Disponible en: http://dx.doi.org/10.1016/S0304-3959(01)00371-2
Rozen TD. Emergency department and inpatient management of status migrainosus and intractable headache. Continuum (Minneap Minn). 2015;21(4 Headache):1004-17. Disponible en: http://dx.doi.org/10.1212/CON.0000000000000191
Iljazi A, Chua A, Rich-Fiondella R, Veronesi M, Melo-Carrillo A, Ashina S, et al. Unrecognized challenges of treating status migrainosus: An observational study. Cephalalgia. 2020;40(8):818-27. Disponible en: http://dx.doi.org/10.1177/0333102420911461
Berk T, Silberstein SD. The use and method of action of intravenous lidocaine and its metabolite in headache disorders. Headache. 2018;58(5):783-9. Disponible en: http://dx.doi.org/10.1111/head.13298
Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, et al. Prevalence of migraine in Latin America. Headache. 2005;45(2):106-17. Disponible en: http://dx.doi.org/10.1111/j.1526-4610.2005.05024.x
Pradilla A G, Vesga A BE, León-Sarmiento FE, GENECO. National neuroepidemiological study in Colombia (EPINEURO). Rev Panam Salud Public. 2003;14(2):104-11. Disponible en: http://dx.doi.org/10.1590/s1020-49892003000700005
Vécsei L, Szok D, Nyári A, Tajti J. Treating status migrainosus in the emergency setting: what is the best strategy? Expert Opin Pharmacother. 2018;19(14):1523-31. Disponible en: http://dx.doi.org/10.1080/14656566.2018.1516205
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-73. Disponible en: http://dx.doi.org/10.1136/bmj.38281.595718.7C
Marmura MJ, Goldberg SW. Inpatient management of migraine. Curr Neurol Neurosci Rep. 2015;15(4):13. Disponible en: http://dx.doi.org/10.1007/s11910-015-0539-z
Woldeamanuel YW, Rapoport AM, Cowan RP. What is the evidence for the use of corticosteroids in migraine? Curr Pain Headache Rep. 2014;18(12):464. Disponible en: http://dx.doi.org/10.1007/s11916-014-0464-x
Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia. 2003;23(10):963-71. Disponible en: http://dx.doi.org/10.1046/j.1468-2982.2003.00623.x
Rosen N, Marmura M, Abbas M, Silberstein S. Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache. 2009;49(2):286-91. Disponible en: http://dx.doi.org/10.1111/j.1526-4610.2008.01281.x
Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: Results from the American Migraine Prevalence and prevention (AMPP) study. Headache. 2016;56(10):1635-48. Disponible en: http://dx.doi.org/10.1111/head.12941
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.